About
Copy Link
Titles
Associate Research Scientist
Biography
I am an Infectious Diseases and Clinical Microbiology Specialist and Data Analyst. I earned my M.D. and completed my residency at the Gulhane Military Medical Academy in Turkey, and previously served as a Yale School of Medicine Research Scholar focused on HIV research. Drawing on my clinical background in medical virology and infection control, my overarching goal today is to advance the understanding and treatment of Wilson Disease by seamlessly integrating traditional clinical medicine with innovative, data-driven approaches.
Last Updated on March 21, 2026.
Appointments
Digestive Diseases
Associate Research ScientistPrimary
Other Departments & Organizations
Education & Training
- Infectious Diseases and Clinical Microbiology Residency
- Gulhane School of Medicine (2006)
- MD
- Gulhane School of Medicine, School of Medicine (1999)
Advanced Training & Certifications
- Blood Bank and Transfusion Medicine
- Gulhane School of Medicine (2010)
Research
Copy Link
Overview
Public Health Interests
Statistical Computing; Hepatitis; Clinical Trials
ORCID
0000-0003-0531-0668
Research at a Glance
Publications Timeline
A big-picture view of Asim Ulcay's research output by year.
49Publications
700Citations
Publications
2019
Neutralization Synergy between HIV-1 Attachment Inhibitor Fostemsavir and Anti-CD4 Binding Site Broadly Neutralizing Antibodies against HIV
Zhang Y, Chapman JH, Ulcay A, Sutton RE. Neutralization Synergy between HIV-1 Attachment Inhibitor Fostemsavir and Anti-CD4 Binding Site Broadly Neutralizing Antibodies against HIV. Journal Of Virology 2019, 93: 10.1128/jvi.01446-18. PMID: 30518644, PMCID: PMC6363990, DOI: 10.1128/jvi.01446-18.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsBMS-626529HIV-1New drugsHuman immunodeficiency virus type 1 gp120Viral EnvViral entryPhase III clinical trialsHIV-1 preventionTreatment of HIVHIV-1 EnvHIV antibodiesLarge molecule therapeuticsHIV infectionClinical trialsHIV preventionHIV pandemicVirus infectionHIV entryAttachment inhibitorsDrug AdministrationNIH45-46HIVCD4Clinical useSingle treatment
2018
Use of quantitative hepatitis B surface antigen levels in the follow-up of HBV-Infected patients with Genotype D
Karagoz E, Tanoglu A, Turhan V, Selek M, Ulcay A, Erdem H, Batirel A. Use of quantitative hepatitis B surface antigen levels in the follow-up of HBV-Infected patients with Genotype D. Medicine Science | International Medical Journal 2018, 515. DOI: 10.5455/medscience.2018.07.8812.Peer-Reviewed Original Research
2017
Noninvasive Models to Predict Liver Fibrosis in Patients with Chronic Hepatitis B: A Study from Turkey
Korkmaz P, Demirturk N, Batırel A, Cem Yardimci A, Cagir U, Atakan Nemli S, Korkmaz F, Zeynep Akcam F, Sener Barut H, Bayrak B, Karakecili F, Tarakci H, Yulugkural Z, Yuksel E, Aktug Demir N, Ural O, Sumer S, Harman R, Kadanali A, Ozturk S, Cetin Akhan S, Eren Tulek N, Keten D, Sener A, Aygen B, Kocagul Celikbas A, Yilmaz Karadag F, Aydin G, Arslan E, Sacligil C, Akengin Ocal G, Tanoglu A, Ulcay A, Karagoz E, Saltoglu N, Sırmatel F, Akdeniz H, Aynıoglu A, Arslan Ozel S, Dirgen Caylak S, Celik I, Alpay Y, Bestepe Dursun Z, Bekcibasi M, Tuncer Ertem G, Tigli A, Sargin Altunok E, Avsar K, Suer K, Sayan M. Noninvasive Models to Predict Liver Fibrosis in Patients with Chronic Hepatitis B: A Study from Turkey. Hepatitis Monthly 2017, In Press DOI: 10.5812/hepatmon.60266.Peer-Reviewed Original ResearchRecurrent Fever of Unknown Origin Associated with Forgotten Dental Root Infection in a Geriatric Patient
Karagoz E, Ulcay A, Suer B, Turhan V, Acar A, Erdem H, Öncül O, Görenek L. Recurrent Fever of Unknown Origin Associated with Forgotten Dental Root Infection in a Geriatric Patient. West Indian Medical Journal 2017 DOI: 10.7727/wimj.2017.012.Peer-Reviewed Original ResearchNoninvasive Models to Predict Liver Fibrosis in Patients with Chronic Hepatitis B: A Study from Turkey
Korkmaz P, Demirturk N, Batırel A, Yardimci A, Cagir U, Nemli S, Korkmaz F, Akcam F, Barut H, Bayrak B, Karakecili F, Tarakci H, Yulugkural Z, Yuksel E, Demir N, Ural O, Sumer S, Harman R, Kadanali A, Ozturk S, Akhan S, Tulek N, Keten D, Sener A, Aygen B, Celikbas A, Karadag F, Aydin G, Arslan E, Sacligil C, Ocal G, Tanoglu A, Ulcay A, Karagoz E, Saltoglu N, Sırmatel F, Akdeniz H, Aynıoglu A, Ozel S, Caylak S, Celik I, Alpay Y, Dursun Z, Bekcibasi M, Ertem G, Tigli A, Altunok E, Avsar K, Suer K, Sayan M. Noninvasive Models to Predict Liver Fibrosis in Patients with Chronic Hepatitis B: A Study from Turkey. Hepatitis Monthly 2017, 17 DOI: 10.5812/hepatmon.60266.Peer-Reviewed Original ResearchCitations
2016
Comparison of the Elecsys HBsAg II Assay and the Architect Assay for Quantification of hepatitis B surface antigen in patients with chronic hepatitis B.
Karagoz E, Selek M, Tanoglu A, Hatipoglu M, Ulçay A, Turhan V. Comparison of the Elecsys HBsAg II Assay and the Architect Assay for Quantification of hepatitis B surface antigen in patients with chronic hepatitis B. Infezioni In Medicina 2016, 24: 287-292. PMID: 28011963.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsAbbott Architect HBsAg assaysOn-treatment patientsHepatitis B surface antigenElecsys HBsAg II assayArchitect HBsAg assayB surface antigenHepatitis B virusArchitect assayHBsAg assaysPearson correlation testQuantification of hepatitis B surface antigenQuantitative hepatitis B surface antigenEffect of antiviral therapyChronic hepatitis BArchitect HBsAg QTCorrelation testBland-Altman analysisNaive patientsCHB patientsHBsAg levelsUntreated patientsInterclass correlation testsAntiviral therapyHepatitis BElecsys assayMean platelet volume and red cell distribution width to platelet ratio for predicting the severity of hepatic fibrosis in patients with chronic hepatitis C
Karagöz E, Tanolu A, Ülçay A, Erdem H, Turhan V, Kara M, Yazgan Y. Mean platelet volume and red cell distribution width to platelet ratio for predicting the severity of hepatic fibrosis in patients with chronic hepatitis C. European Journal Of Gastroenterology & Hepatology 2016, 28: 744-748. PMID: 27101403, DOI: 10.1097/meg.0000000000000647.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsRed cell distribution width to platelet ratioMean platelet volumeChronic hepatitis CRed cell distribution widthSeverity of fibrosisCell distribution widthCut-off valuePlatelet ratioFibrosis scoreHepatitis CPlatelet volumeDistribution widthRed cell distribution width to platelet ratio valueHepatitis C patientsSeverity of hepatic fibrosisRoutine biochemical parametersIshak scoring systemPlatelet distribution widthHistological liver damageSPSS 15 softwareBlood count variablesAssociated with severityComplete blood count variablesLiver biopsy samplesWhite blood cellsCranial imaging findings in neurobrucellosis: results of Istanbul-3 study
Erdem H, Senbayrak S, Meriç K, Batirel A, Karahocagil M, Hasbun R, Sengoz G, Karsen H, Kaya S, Inal A, Pekok A, Celen M, Deniz S, Ulug M, Demirdal T, Namiduru M, Tekin R, Guven T, Parlak E, Bolukcu S, Avci M, Sipahi O, Ozturk-Engin D, Yaşar K, Pehlivanoglu F, Yilmaz E, Ates-Guler S, Mutlu-Yilmaz E, Tosun S, Sirmatel F, Sahin-Horasan E, Akbulut A, Oztoprak N, Cag Y, Kadanali A, Turgut H, Baran A, Gul H, Sunnetcioglu M, Haykir-Solay A, Denk A, Inan A, Ayaz C, Ulcay A, Kose S, Agalar C, Elaldi N. Cranial imaging findings in neurobrucellosis: results of Istanbul-3 study. Infection 2016, 44: 623-631. PMID: 27138335, DOI: 10.1007/s15010-016-0901-3.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsDuration of symptomsWhite-matter involvementMagnetic resonance imagingCentral nervous systemInflammatory findingsVascular involvementImaging findingsComputerized tomographySpinal nerve root enhancementNerve root enhancementCranial nerve involvementAbnormal imaging findingsBasal meningeal enhancementMagnetic resonance imaging scansAbnormal neuroimaging findingsCSF protein levelsPrevalence of imaging abnormalitiesCranial imaging findingsNeurobrucellosis patientsCerebral ischemic changesLeptomeningeal involvementNormal CTNerve involvementBrain abscessReferral centerIntegrase Strand Transfer Inhibitors (INSTIs) Resistance Mutations in HIV-1 Infected Turkish Patients
Sayan M, Gündüz A, Ersöz G, İnan A, Deveci A, Özgür G, Sargın F, Karagöz G, İnci A, İnan D, Ülçay A, Karaoğlan İ, Kaya S, Kutlu S, Süer K, Çağatay A, Akalın H. Integrase Strand Transfer Inhibitors (INSTIs) Resistance Mutations in HIV-1 Infected Turkish Patients. HIV Research & Clinical Practice 2016, 17: 109-113. PMID: 27125365, DOI: 10.1080/15284336.2016.1153303.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsIntegrase strand transfer inhibitorsIntegrase strand transfer inhibitor resistance mutationsHIV-1-infected patientsARV-experienced patientsStrand transfer inhibitorsResistance mutationsHIV-1Turkish patientsIntegrase strand transfer inhibitor therapyMedian CD4(+) T-cellHIV-1 drug resistance mutationsMedian HIV-1 RNAHIV-1 pol geneCD4(+) T cellsTransfer inhibitorsART-experienced patientsINSTI resistance mutationsHIV-1 RNADrug resistance mutationsHIV-1 genomeMedian ageT cellsClinical characteristicsHIV managementPatientsEvaluation of Dual Therapy in Real Life Setting in Treatment-Naïve Turkish Patients with HCV Infection: A Multicenter, Retrospective Study
Gürbüz Y, Tülek N, Tütüncü E, Koruk S, Aygen B, Demirtürk N, Kınıklı S, Kaya A, Yıldırmak T, Süer K, Korkmaz F, Ural O, Akhan S, Günal Ö, Tuna N, Köse Ş, Gönen İ, Örmen B, Türker N, Saltoğlu N, Batırel A, Tuncer G, Bulut C, Sırmatel F, Ulçay A, Karagöz E, Tosun D, Şener A, Aynıoğlu A, Altunok E. Evaluation of Dual Therapy in Real Life Setting in Treatment-Naïve Turkish Patients with HCV Infection: A Multicenter, Retrospective Study. Balkan Medical Journal 2016, 33: 18-26. PMID: 26966614, PMCID: PMC4767305, DOI: 10.5152/balkanmedj.2015.15859.Peer-Reviewed Original ResearchCitationsConceptsSustained virological response ratesSustained virological responseTreatment due to adverse effectsBaseline viral loadPeginterferon alpha-2aViral loadVirological responseDual therapyAlpha-2aAlpha-2bTreatment of chronic hepatitis C patientsTurkish patientsTreated with peginterferon alpha-2aPredictor of sustained virological responseGenotype 1Combination of peginterferon-alphaHigh sustained virological responseLow baseline viral loadIntroduction of direct-acting antiviralsChronic hepatitis C patientsLiver diseaseGenotype 4 patientsEarly virological responseGenotype 1 patientsPeginterferon alpha-2b
Academic Achievements & Community Involvement
Copy Link
Activities
activity The Turkish Clinical Microbiology and Infectious Diseases Society (KLIMIK)
2006 - PresentProfessional OrganizationsMember
News & Links
Copy Link
Get In Touch
Copy Link
Contacts
Email